Table 1 Baseline characteristics before and after propensity score matching.
Before PSM | After PSM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Total | BSV | TAF | P | SMD | Total | BSV | TAF | P | SMD | |
(n = 41,587) | (n = 2,358) | (n = 39,499) | (n = 8,956) | (n = 2,239) | (n = 6,717) | |||||
Age (years) | 51.1 ± 12.2 | 50.7 ± 11.0 | 51.1 ± 12.2 | 0.078 | − 0.034 | 51.0 ± 12.0 | 50.7 ± 11.0 | 51.1 ± 12.3 | 0.167 | − 0.032 |
Male | 24,241 (57.9) | 1,407 (59.7) | 22,834 (57.8) | 0.076 | 0.038 | 5,221 (58.3) | 1,335 (59.6) | 3,886 (57.9) | 0.141 | 0.036 |
Duration of antiviral medication (days) | 852.3 ± 508.5 | 863.1 ± 480.8 | 851.6 ± 510.1 | 0.263 | 0.023 | 833.4 ± 475.7 | 831.8 ± 473.3 | 833.9 ± 476.6 | 0.860 | − 0.004 |
CCI score | 2.4 ± 0.9 | 2.4 ± 0.9 | 2.4 ± 0.9 | 0.067 | 0.040 | 2.4 ± 0.9 | 2.4 ± 1.0 | 2.4 ± 0.9 | 0.058 | 0.048 |
Presence of cirrhosis | 8,759 (20.9) | 476 (20.2) | 8,283 (21.0) | 0.364 | 1,838 (20.5) | 457 (20.4) | 1,381 (20.6) | 0.880 | ||
Presence of decompensation | 3,289 (7.9) | 176 (7.5) | 3,113 (7.9) | 0.464 | 663 (7.4) | 170 (7.6) | 493 (7.3) | 0.692 | ||
Median follow-up duration (year) | 2.4 ± 1.2 | 2.5 ± 1.1 | 2.4 ± 1.2 | < 0.001 | 2.3 ± 1.1 | 2.4 ± 1.0 | 2.3 ± 1.1 | 0.033 | ||
